Antonio Costanzo

Antonio Costanzo

Milan, Italy

Lecture Title: Genotype mediated therapy in Psoriasis

Selected Publications

Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G; SUPREME study group. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16705.

Galluzzo M, Boca AN, Botti E, Potenza C, Malara G, Malagoli P, Vesa S, Chimenti S, Buzoianu AD, Talamonti M, Costanzo A. IL12B (p40) Gene Polymorphisms  Contribute to Ustekinumab Response Prediction in Psoriasis. Dermatology. 2016;232(2):230-6.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014 Dec 3;5:5621.

Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, Chimenti S, Costanzo A. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013 Aug;169(2):458-63

Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola F, Ganci F, Castrignanò T, Pesole G, Chimenti S, Guerrini L, Fanciulli  M, Blandino G, Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13710-5.

Moretti F, Marinari B, Lo Iacono N, Botti E, Giunta A, Spallone G, Garaffo G, Vernersson-Lindahl E, Merlo G, Mills AA, Ballarò C, Alemà S, Chimenti S, Guerrini L, Costanzo A. A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. J Clin Invest. 2010 May 3;120(5):1570-7.

Marinari B, Moretti F, Botti E, Giustizieri ML, Descargues P, Giunta A, Stolfi C, Ballaro C, Papoutsaki M, Alemà S, Monteleone G, Chimenti S, Karin M, Costanzo A. The tumor suppressor activity of IKKalpha in stratified epithelia is  exerted in part via the TGF-beta antiproliferative pathway. Proc Natl Acad Sci U  S A. 2008 Nov 4;105(44):17091-6.

Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, Giustizieri ML,  Pacciani V, Mazzotta A, Campione E, Macdonald TT, Chimenti S, Pallone F, Costanzo A, Monteleone G. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med. 2009 Sep;15(9):1013-5.

Pediconi N, Ianari A, Costanzo A*, Belloni L, Gallo R, Cimino L, Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A, Levrero M. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol. 2003 Jun;5(6):552-8. * Co-first author

Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell. 2002 Jan;9(1):175-86.

Gong JG, Costanzo A*, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999 Jun 24;399(6738):806-9. * Co-first author

 Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero  M. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science. 1997 Jan 10;275(5297):200-3.

EADV Guest Lecture